BioAlliance Pharma: Approval to start ReLive (Livatag) Phase III Clinical Trial in Primary Liver Cancer in the U.S. and Germany

16-12-2013 Business Wire HealthComments (0)

BioAlliance PharmaPharmaceutical

Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology and to supportive care products, announces that it has received authorization to start its Phase III ReLive clinical trial in primary liver cancer in the U.S. (IND approval), following the review of the Livatag development program by the FDA, as well as in Germany after the German health agency green light. “The deployment strategy planned

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top